Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 7/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810162 | 0.82 | CETP (0.49) | CETPCYP2C19MME | |
| SCHEMBL727220 | 0.82 | CYP2C19 (0.50) | CETPCYP2C19MME | |
| SCHEMBL2702660 | 0.82 | CETP (0.39) | CETPMME | |
| SCHEMBL9971636 | 0.81 | CETP (0.48) | CETPCYP2C19MME | |
| SCHEMBL781736 | 0.81 | CETP (0.48) | CETPCYP2C19MME | |
| SCHEMBL9974581 | 0.81 | CETP (0.48) | CETPCYP2C19MME | |
| SCHEMBL2203045 | 0.79 | CETP (0.47) | CETPCYP2C19MME | |
| SCHEMBL9972631 | 0.78 | CETP (0.47) | CETPCYP2C19MME | |
| SCHEMBL1421653 | 0.78 | CETP (0.49) | CETPCYP2C19MME | |
| SCHEMBL11291533 | 0.77 | CYP2C19 (0.41) | CETPCYP2C19MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603816-B2 | Process | HOFFMANN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| CN-103261155-B | Method by the hydrogenation preparation aromatic mercaptans derivant of disulphide | 霍夫曼-拉罗奇有限公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-2448918-B1 | PREPARATION AND CRYSTALLISATION OF S-[2-[1-(2-ETHYLBUTYL)CYCLOHEXYLCARBONYLAMINO]-PHENYL]-2-METHYLTHIOPROPIONATE | HOFFMANN LA ROCHE (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-9000045-B2 | CETP activity inhibitors | JAPAN TOBACCO INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8765989-B2 | Process | HOFFMANN - LA ROCHE INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765989-B2 | Process | HOFFMANN - LA ROCHE INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140171502-A1 | New Process | HOFFMANN-LA ROCHE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8664403-B2 | Process | HOFFMANN-LA ROCHE INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130079541-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079541-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-7271196-B2 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TABACCO INC. (JP) | 2007-09-18 | — | — | US | disclosed |
| WO-2007051714-A1 | NOVEL PROCESS FOR THE PREPARATION OF ACID CHLORIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | WO | disclosed |
| US-20070100154-A1 | Process for the production of acid chlorides | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-03 | — | — | US | disclosed |
| EP-1710231-A1 | CETP activity inhibitors | Japan Tobacco, Inc. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-1020439-B1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6753346-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS | JAPAN TOBACCO INC. (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6426365-B1 | Anticholesterol agents; Cholesterol ester transfer protein (CETP); including dalcetrapib, S-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino) phenyl) 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | CETP, MTTP, LCAT | CETP 1/4885CYP2C19 2459/4885MME 671/4885 |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | CETP 1/4885CYP2C19 1065/4885MME 466/4885 |
| US-20140171502-A1 | New Process | CYP3A4, TPMT, CYP4B1 | CETP 313/4885CYP2C19 95/4885MME 191/4885 |
| US-20130079541-A1 | NOVEL PROCESS | CYP3A4, CYP4B1, CYP11B2 | CETP 448/4885CYP2C19 122/4885MME 579/4885 |
| US-20070100154-A1 | Process for the production of acid chlorides | CLIC1, ACAD9, ASIC1 | CETP 3007/4885CYP2C19 56/4885MME 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.